Published in Bioanalysis on March 01, 2012
A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature (2012) 8.10
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol (2008) 5.54
Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell (2007) 4.11
Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol (2005) 3.00
Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med (2011) 2.51
Blocking neuropilin-2 function inhibits tumor cell metastasis. Cancer Cell (2008) 2.35
An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell (2011) 2.14
Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer. Cancer Res (2010) 1.98
Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nat Chem Biol (2010) 1.94
VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis. Proc Natl Acad Sci U S A (2009) 1.91
A therapeutic antibody targeting BACE1 inhibits amyloid-β production in vivo. Sci Transl Med (2011) 1.75
Neuropilin-1 binds to VEGF121 and regulates endothelial cell migration and sprouting. J Biol Chem (2007) 1.73
Neuropilin-2 mediates VEGF-C-induced lymphatic sprouting together with VEGFR3. J Cell Biol (2010) 1.72
A dimeric viral SET domain methyltransferase specific to Lys27 of histone H3. Nat Struct Biol (2003) 1.67
Structural studies of neuropilin/antibody complexes provide insights into semaphorin and VEGF binding. EMBO J (2007) 1.43
Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats. Bioconjug Chem (2011) 1.40
Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-{alpha} antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys. Drug Metab Dispos (2010) 1.38
Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy. Clin Cancer Res (2010) 1.29
Function blocking antibodies to neuropilin-1 generated from a designed human synthetic antibody phage library. J Mol Biol (2006) 1.29
Robo4 maintains vessel integrity and inhibits angiogenesis by interacting with UNC5B. Dev Cell (2011) 1.29
Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc Natl Acad Sci U S A (2013) 1.20
Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signaling. J Biol Chem (2010) 1.15
Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4. MAbs (2011) 1.06
Structure-based design of potent and selective 3-phosphoinositide-dependent kinase-1 (PDK1) inhibitors. J Med Chem (2011) 1.05
Synthetic anti-BR3 antibodies that mimic BAFF binding and target both human and murine B cells. Blood (2006) 1.02
Anti-BR3 antibodies: a new class of B-cell immunotherapy combining cellular depletion and survival blockade. Blood (2007) 1.01
Differential regulation of insulin resistance and hypertension by sex hormones in fructose-fed male rats. Am J Physiol Heart Circ Physiol (2005) 1.01
Genetic analysis reveals that amyloid precursor protein and death receptor 6 function in the same pathway to control axonal pruning independent of β-secretase. J Neurosci (2014) 0.98
Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier. Sci Transl Med (2013) 0.97
Subcutaneous bioavailability of therapeutic antibodies as a function of FcRn binding affinity in mice. MAbs (2012) 0.96
Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants. J Exp Med (2014) 0.96
Surface expression of precursor N-cadherin promotes tumor cell invasion. Neoplasia (2010) 0.95
Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering. J Med Chem (2014) 0.95
Thin film measurement system for moving objects based on a laterally distributed linear variable filter spectrometer. Rev Sci Instrum (2012) 0.92
A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol (2014) 0.92
Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase. J Med Chem (2010) 0.92
Maximizing tumour exposure to anti-neuropilin-1 antibody requires saturation of non-tumour tissue antigenic sinks in mice. Br J Pharmacol (2012) 0.92
In vivo activity of novel capecitabine regimens alone and with bevacizumab and oxaliplatin in colorectal cancer xenograft models. Mol Cancer Ther (2009) 0.91
MR angiogenesis imaging with Robo4- vs. alphaVbeta3-targeted nanoparticles in a B16/F10 mouse melanoma model. FASEB J (2010) 0.91
N-cadherin prodomain processing regulates synaptogenesis. J Neurosci (2012) 0.90
Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose. Cancer Chemother Pharmacol (2011) 0.87
Development and preclinical characterization of a humanized antibody targeting CXCL12. Clin Cancer Res (2013) 0.86
Micro-volume wall-less immunoassays using patterned planar plates. Lab Chip (2013) 0.86
Experimental evaluation of the accuracy of skin dose calculation for a commercial treatment planning system. J Appl Clin Med Phys (2008) 0.86
Identification of circulating neuropilin-1 and dose-dependent elevation following anti-neuropilin-1 antibody administration. MAbs (2009) 0.86
Identification of a GJA3 mutation in a Chinese family with congenital nuclear cataract using exome sequencing. Indian J Biochem Biophys (2013) 0.85
MiR-224 impairs adipocyte early differentiation and regulates fatty acid metabolism. Int J Biochem Cell Biol (2013) 0.85
Influence of anti-washout agents on the rheological properties and injectability of a calcium phosphate cement. J Biomed Mater Res B Appl Biomater (2007) 0.85
A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors. Invest New Drugs (2014) 0.84
Pharmacokinetic and pharmacodynamic analysis of circulating biomarkers of anti-NRP1, a novel antiangiogenesis agent, in two phase I trials in patients with advanced solid tumors. Clin Cancer Res (2012) 0.84
Novel cyclohexyl-amides as potent antibacterials targeting bacterial type IIA topoisomerases. Bioorg Med Chem Lett (2011) 0.84
Genome-wide scan identifies variant in TNFSF13 associated with serum IgM in a healthy Chinese male population. PLoS One (2012) 0.83
Effect of immune complex formation on the distribution of a novel antibody to the ovarian tumor antigen CA125. Drug Metab Dispos (2010) 0.83
Comparative preclinical drug metabolism and pharmacokinetic evaluation of novel 4-aminoquinoline anti-malarials. J Pharm Sci (2009) 0.83
Exaggerated hypotensive effect of vascular endothelial growth factor in spontaneously hypertensive rats. Hypertension (2002) 0.83
Genetically modified cotton and farmers' health in China. Int J Occup Environ Health (2004) 0.83
Monopalmityloxy shikimic acid: enzymatic synthesis and anticoagulation activity evaluation. Appl Biochem Biotechnol (2008) 0.82
Technology comparisons for anti-therapeutic antibody and neutralizing antibody assays in the context of an anti-TNF pharmacokinetic study. J Immunol Methods (2009) 0.82
Analytical solution of four-mode coupling in shear strain loaded fiber Bragg grating sensors. Opt Lett (2009) 0.82
Surface properties of submicrometer silica spheres modified with aminopropyltriethoxysilane and phenyltriethoxysilane. J Colloid Interface Sci (2006) 0.81
Anti-neuropilin-1 (MNRP1685A): unexpected pharmacokinetic differences across species, from preclinical models to humans. Pharm Res (2012) 0.80
Physiologically based pharmacokinetic modeling as a tool to predict drug interactions for antibody-drug conjugates. Clin Pharmacokinet (2015) 0.80
Simple quantitative live cell and anti-idiotypic antibody based ELISA for humanized antibody directed to cell surface protein CD20. J Immunol Methods (2004) 0.80
Improvement in cardiac function of diabetic rats by bosentan is not associated with changes in the activation of PKC isoforms. Mol Cell Biochem (2006) 0.80
Autonomic Remodeling: How Atrial Fibrillation Begets Atrial Fibrillation in the First 24 Hours. J Cardiovasc Pharmacol (2015) 0.79
Dose dependent pharmacokinetics, tissue distribution, and anti-tumor efficacy of a humanized monoclonal antibody against DLL4 in mice. MAbs (2014) 0.79
Hutchinson-Gilford progeria syndrome accompanied by severe skeletal abnormalities in two Chinese siblings: two case reports. J Med Case Rep (2013) 0.78
Computational and experimental studies on human misshapen/NIK-related kinase MINK-1. Curr Med Chem (2004) 0.77
[Senescent endothelial dysfunctions were mediated by S1P2 receptor in cultured human umbilical vein endothelial cells]. Zhong Nan Da Xue Xue Bao Yi Xue Ban (2012) 0.77
Senescent endothelial dysfunction is attributed to the up-regulation of sphingosine-1-phosphate receptor-2 in aged rats. Mol Cell Biochem (2011) 0.77
Two new compounds from an endophytic fungus Alternaria solani. J Asian Nat Prod Res (2012) 0.77
Discovery of a new series of Aurora inhibitors through truncation of GSK1070916. Bioorg Med Chem Lett (2010) 0.77
Population pharmacokinetic and pharmacodynamic modeling of MNRP1685A in cynomolgus monkeys using two-target quasi-steady-state (QSS) model. J Pharmacokinet Pharmacodyn (2012) 0.76
Intercalative interaction of asymmetric copper(II) complex with DNA: experimental, molecular docking, molecular dynamics and TDDFT studies. J Inorg Biochem (2013) 0.76
On-line thickness measurement for two-layer systems on polymer electronic devices. Sensors (Basel) (2013) 0.75
Static hyperspectral fluorescence imaging of viscous materials based on a linear variable filter spectrometer. Sensors (Basel) (2013) 0.75
Impact of contact force technology on reducing the recurrence and major complications of atrial fibrillation ablation: A systematic review and meta-analysis. Anatol J Cardiol (2017) 0.75
Comparison of dye adsorption by mesoporous hybrid gels: understanding the interactions between dyes and gel surfaces. J Colloid Interface Sci (2006) 0.75
Unidirectional scattering induced by the toroidal dipolar excitation in the system of plasmonic nanoparticles. Opt Express (2017) 0.75
Topological interface states in multiscale spoof-insulator-spoof waveguides. Opt Lett (2016) 0.75
[Regulation mechanism of eIF3 P170 on developing myocardial cell cycle]. Zhong Nan Da Xue Xue Bao Yi Xue Ban (2013) 0.75
1H, 13C and 15N resonance assignments for the N-cadherin prodomain. J Biomol NMR (2004) 0.75
Static Fourier transform infrared spectrometer. Opt Express (2016) 0.75
Engineered heart tissue transplantation alters electrical-conduction function in rats with myocardial infarction. Life Sci (2014) 0.75
[Construction of eukaryotic expression vector of human TSARG4 and establishment of its stable transfected HeLa cell line]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi (2009) 0.75
Bis(trimethoxysilylpropyl)amine and tetraethoxysilane derived gels as effective controlled release carriers for water-soluble drugs of small molecules. Colloids Surf B Biointerfaces (2006) 0.75
[Clinical effects of different ways of mechanical ventilation combined with pulmonary surfactant in treatment of acute lung injury/acute respiratory distress syndrome in neonates: a comparative analysis]. Zhongguo Dang Dai Er Ke Za Zhi (2016) 0.75
Pharmacokinetics and ADME characterizations of antibody-drug conjugates. Methods Mol Biol (2013) 0.75
Simultaneous displacement and slope measurement in electronic speckle pattern interferometry using adjustable aperture multiplexing. Appl Opt (2016) 0.75